Purpose: The efficacy, safety, and dose distribution of neutron capture therapy (NCT) were evaluated in 15 patients with newly diagnosed glioblastoma.
Introduction
Glioblastoma multiforme (GBM) is one of the most frequent primary brain tumors in adults. Despite recent advancements in image-guided neurosurgery, conformal radiation and chemotherapeutic agents, GBM is still an incurable disease that recurs easily due to rapid growth and microscopic invasion to the surrounding normal brain tissue.
Concomitant and adjuvant use of temozolomide with conventional photon radiotherapy, the new standard post-operative therapy for GBM, has demonstrated a significant survival advantage compared to radiotherapy alone, and shows minimal additional toxicity. The median overall survival (OS) time in a randomized control trial was 14.6 M with temozolomide plus radiotherapy and 12.1 M with radiotherapy alone [1] .
The dose of radiation required to completely kill GBM cells has not yet been determined, however, previous reports imply that at least 90 Gy must be used to achieve better local control [2, 3] . In general, such high-dose radiation is considered to be in excess of the tolerance dose of normal brain tissue which is used in conventional fractionated photon radiotherapy. Several randomized trials have shown a survival benefit of conventional fractionated photon radiotherapy at total doses of 45 to 60 Gy; the median OS in these trials was 5.8 M to 15.5 M [4-7] . Most subsequent dose escalation studies have been designed as case series of small numbers of selected patients who underwent additional stereotactic radiosurgery, fractionated proton beam radiation or other conformal radiotherapy. The better outcome following these radiotherapies, in which median OS varies from 9.5 M to 25 M, is in part the result of patient selection [2, 3, [8] [9] [10] . There is an urgent need for a tumor-selective high-dose therapy that would encompass the main tumor mass as well as microscopic invasion whilst avoiding radiation damage to the surrounding normal brain tissue.
Neutron capture therapy (NCT) preferentially destroys 10 B-loaded tumor cells, while sparing the normal tissue without 10 B, based on a nuclear reaction between 10 B, a stable non-radioactive isotope of boron, and low energy thermal neutrons, which release high linear energy transfer (LET) α ( 4 He) particles and 7 Li particles with a path-length of one cell diameter (-10 μm) through the boron neutron capture reaction, 10 B(n, α) 7 Li. Therefore, NCT theoretically allows a unique tumor-cell-selective radiotherapy existing of all radiation therapy modalities. The effectiveness of NCT is highly dependent on the optimization of the accumulation of selective 10 B-containing agent(s) in tumor cells as well as on the presence of sufficient thermal neutrons even at the deepest levels. Although there have been a great number of pre-clinical and clinical investigations over the last six decades [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [35] [36] [37] [38] [39] [40] [41] [42] , this emerging therapeutic modality remains immature compared to recent systematically computerized and accurate conformal radiation modalities. There are some issues that remain to be resolved, given that neutron sources are restricted to nuclear reactors, limiting their availability for conformal neutron beam irradiation and more efficient 10 B-containing agents.
Recent clinical studies on boron NCT (BNCT) have focused on high-grade glioma and malignant meningioma [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , head and neck tumors [24, 29] , cutaneous melanoma [25, 26] and lung and liver metastases [27, 28] as potential candidates for NCT. To the best of our knowledge, no clinical data have yet been published on NCT in a randomized controlled trial. With respect to the case series as Phase I or Phase II NCT trials for GBM, the median OS time varied from 13 M to 20.7 M. Although these values are similar to those of postoperative conventional photon fractionation and standard chemotherapy [1] , they imply that NCT may be at least partially effective. In the present pilot study, survival benefits, safety and dose distribution in tumor and normal tissue were evaluated in GBM patients who were treated with either the former intra-operative NCT (IO-NCT) or the current less-invasive external beam NCT (EB-NCT).
Materials and Methods
As boron delivery agents for NCT, sulfhydryl borane Na 2 B 12 H 11 SH (BSH) and p-dihydroxyboryl-phenylalanine (BPA) were used in this study. BSH (5 g/body, 1 hour i.v. infusion) was administered intravenously 12 hours before neutron irradiation in IO-NCT (protocol-1) and EB-NCT (protocol-2). Additionally, water soluble fructose complex of BPA (250 mg/kg, 1 hour i.v. infusion) was given 1.5 hour before irradiation for the 8 patients who underwent EB-NCT. Blood samples were drawn serially after intravenous injection to estimate the blood boron level. The blood samples were measured by inductively coupled plasma-atomic emission spectroscopy (ICP-AES) and confirmed by prompt gamma ray analysis (PGA). A tumor-to-BSH-mediated blood 10 B concentration ratio of 1.0 was used to estimate the boron dose to be delivered to the tumor tissue. 18 F-labeled BPA positron emission tomography (PET) was performed prior to EB-NCT in order to calculate the lesion-to-normal ratio of BPA-mediated 10 B for estimating the BPA-mediated tumor dose in EB-NCT Neutron irradiation in both protocol-1 and protocol-2 was performed in a single fraction using an epithermal or epithermal-thermal mixed beam of Japan Research Reactor No. 4 (JRR-4). The beam characteristics have been described elsewhere [30] . Briefly, the thermal (<0.53 eV), epithermal (0.53 eV-10 keV) and fast (>10 keV) neutron flux and gamma ray absorbed dose for the epithermal beam were 3.6 x 10 8 n cm -2 s -1 , 2.2 x 10 9 n cm -2 s -1 , 1.1 x 10 8 n cm -2 s -1 and 2.4 Sv/h, respectively, at a reactor power of 3.5 MW. The thermal, epithermal and fast neutron flux and gamma ray absorbed dose for the epithermal-thermal beam were 2.0 x 10 9 n cm -2 s -1 , 9.0 x 10 8 n cm -2 s -1 , 3.6 x 10 5 n cm -2 s -1 and 3.6 Sv/h, respectively. Additional photon irradiation, at a total X-ray dose of 30 Gy in 15 fractions or 30.6 Gy in 17 fractions, was given to high-intensity areas on T2-weighted magnetic resonance (MR) images to compensate for insufficiency of the dose distribution in protocol-2 relative to protocol-1 (Fig. 1) .
The photon-equivalent BNCT dose was calculated by multiplied the weighting factor to account for the increased biological effectiveness of the high-LET dose components.; α and 7 Li particles through the boron neutron capture reaction, 10 The clinical trial was closed because of neutron beam availability at JRR-4 which has been reconstructed for the improvement of a reactor core.
Between 1998 and 2007, we treated 71 patients aged 31 to 84 years (median, 60) with newly diagnosed, histologically confirmed GBM. Eligibility of the patients was decided by more than three neurosurgeons and two radiotherapists. Fifteen eligible patients with signed informed consent who underwent maximal safe resection were selected as participants in the present study (protocol-1, n=7; protocol-2, n=8); Supratentorial unilateral tumors located no deeper than 7 cm from the brain surface, with a Karnofsky Performance Status (KPS) of 50 or more, who had undergone no previous chemotherapy or radiotherapy and no previous therapy for any other cancers, and who had no allergy to BSH or BPA. None of the patients in this series had a previous malignancy.
The patients' characteristics are shown in Table 1 . The median age at primary diagnosis was 57 years (range, 32-76). All patients underwent surgical removal before BNCT, which consisted of gross total removal in 4 (26.7%), partial removal in 10 (66.7%) and biopsy in 1 (6.6%). Five of the 7 protocol-1 patients were described previously in an interim report [11] . The median age of the protocol-1 patients was 51 years (range, and that of the protocol-2 patients was 65 years (range, . The median interval between surgery and NCT was 40 days (range, 29-95) in the protocol-1 group and 28 days (range, Survival time and survival rate were estimated using the Kaplan-Meier method to assess the efficacy of NCT. The log-rank test was used to compare survival times in each type of NCT. These statistical analyses were performed using SPSS, version 15.0J (SPSS Japan, Inc., Tokyo, Japan).
Results
The blood boron concentration at the time of neutron irradiation averaged 32.9+12. Fig. 2A, 2B) . The 1-and 2-year survival rates were 80.0% and 53.3%, respectively. Treatment of tumor progression included neurosurgical resection (n=7) and chemotherapy (n=5), and no patient underwent a second course of radiation.
Discussion
Postoperative NCT following debulking surgery in 15 selected patients with newly diagnosed GBM was found to compare favorably with other series of conventional or high-dose radiotherapies [1] [2] [3] . No serious adverse events were observed in the patients who had better neutron shielding.
The results of the present study could not be directly compared to those of historical controls or to those previously reported in a number of publications because of the present small case series of selected patients, which was a major limitation. However, the prognostic factor-based classifications utilized in the comparison of similar small cohorts [2, 31, 32] , suggest that these relatively positive data are unlikely to reflect patient selection alone. In a subanalysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial on conventional radiotherapy and temozolomide for newly diagnosed GBM, the median OSs in EORTC-RPA Classes III, IV and V were 17, 15 and 10 M, respectively [32] . The most favorable 2-year rate (43.4%) was also scored in Class III. Curran et al. report that the OS after surgery and several radiation regimens using 60 Gy to 81.6 Gy for 1578 patients entered in three RTOG trials were categorized into four (III to VI) of 6 classes with median OSs for Classes III, IV, V and VI of 17.9, 11.1, 8.9 and 4.6M, respectively. The most favorable 2-year rate (35%) was also scored in Class III. Moreover, in high-dose radiation therapy using a proton beam, RTOG prognostic Classes III, IV and V had median OSs of 23, 17 and 14 M, respectively, and Class III had a 2-year survival rate of 34% [2] . In the present series, only 2 of 15 patients (13.3%) were categorized as RTOG Class III and 3 of 15 (20%) were categorized as EORTC Class III. It is noteworthy that the median OS (25.7 M) and 2-year survival rate (53.3%) in the present series appear to be superior to those of RTOG Class III and EORTC Class III in both standard therapy and reported high-dose therapy. In a previous nonrandomized trial of high-dose radiation with radiosurgery boost, reoperation was performed in half of the patients. Histopathological diagnosis showed half of these had radiation necrosis [33] . Reoperation has been shown to be a positive prognostic factor in the patients with GBM who underwent high-dose radiotherapy [2, 33] . In this series, 7 patients with post-NCT deterioration on MR images suffered neurological deterioration with minimal performance decline, and had a subsequent resection.
Pathological diagnosis was recurrent tumor in 2 (case 6, 8), whereas radiation necrosis with or without tumor cells in 5 (case 7, 12, 13, 14, 15) .
Hatanaka and Nakagawa treated more than 200 patients with high-grade glioma with BSH-mediated IO-NCT, achieving a median OS of 22.9 M for GBM [35] . We previously reported 9 patients (GBM in 5, anaplastic astrocytomas in 4) with high-grade gliomas who were treated with BSH-mediated IO-NCT using a mixed epithermal beam of JRR-4 [11] . The median OS for the 5 GBM patients was 23.2 M. IO-NCT under 2 different protocols reported by Kageji [14] showed median OSs for higher and lower dose groups of 19.5 and 15.3 M, respectively. In the present series, additional photon fractionation and the combination of two boron agents were employed in EB-NCT, resulting in at least identical 2-year survival rates in EB-NCT (66.7%), compared to IO-NCT (42.9%). The use of additional photon radiation was based on the experimental data of Barth et al., which showed that the combination of BNCT and photon irradiation could enhance therapeutic effects in tumor-bearing rats [36] . BSH biodistribution studies have suggested that the primary mode of selective BSH distribution is passive diffusion from blood to tumor tissue via the disrupted blood brain barrier (BBB) [37, 38] . The combination of BPA and BSH [12, 39] as well as a longer infusion of BPA [18,40,41] appear to minimize the heterogeneous 10 B distribution in both experimental and clinical situations.
It has been reported that the majority of central nervous system toxicities in NCT are acute, self-limiting and primarily related to a temporal increase in intracranial pressure [20] . A tumor volume of more than 60 cm 3 , an increased average brain dose, and an increased number of irradiation fields were found to lead to a higher incidence of such toxicities. An average brain dose of 6.2 Gy-Eq was associated with a 50% incidence of somnolence. As a consequence of the smaller tumor volume of 18.6+12.2 cm 3 and rather localized dose planning, lower average brain doses (3.9+1.8 Gy) were used in the present series compared to previously reported doses.
The higher than average brain dose in the IO-NCT group (5.1+2.2 Gy) compared to the EB-NCT group (3.1+0.4 Gy) may have contributed to the higher incidence of toxicities.
In conclusion, although NCT is the most complicated radiotherapy, it may be a valuable future alternative treatment for cancer that invades the surrounding healthy normal tissue, and may be preferable to currently existing high-conformal radiation therapies, since in theory it allows tumor-cell-selective high-dose radiation while sparing normal cells. Because of the limitations of the present NCT pilot study for the newly diagnosed GBM without the contemporary control arm, it is not convincing whether the neutron capture reaction is functioning enough to control tumors and led to distinct survival benefits. Randomized trials of comparably selected patients are required to demonstrate conclusively that prolonged survival is a result of this tumor-selective radiotherapy. It is suggested that post-operative EB-NCT is effective for newly-diagnosed glioblastoma and is less invasive than IO-NCT. Future optimization of tumor-targeting boron agents and their delivery, combination with other modalities, and the development of an in-hospital accelerator-based neutron source will be required for enhancing the therapeutic effectiveness of BNCT [13] .
